Description

Dynavax Technologies Corporation operates as a biopharmaceutical firm, primarily dedicated to the research, development, and commercialization of innovative vaccines within the United States. Its leading product is HEPLISAV-B, a hepatitis B vaccine available in both the U.S. and European markets, designed to protect adults aged 18 and above from all known subtypes of the hepatitis B virus. The company also manufactures and provides CpG 1018, an adjuvant critical to the formulation of HEPLISAV-B. Dynavax has established various strategic partnerships, including a collaborative agreement with Valneva Scotland Limited, an understanding with Serum Institute of India Pvt. Ltd., and a sublicense deal with Merck, Sharp & Dohme Corp. Originally incorporated in 1996 under the name Double Helix Corporation, the company rebranded as Dynavax Technologies Corporation in September of that same year, with its corporate headquarters situated in Emeryville, California.